Google
GSK Stock Analysis — GLAXOSMITHKLINE PLC ADR (Healthcare >> Drug Manufacturers - General)
GSK FAQ
What is GSK's P/E ratio?
GLAXOSMITHKLINE PLC ADR (GSK) currently trades at a P/E ratio of 21.64.
What is GSK's ROE?
GLAXOSMITHKLINE PLC ADR reports a Return on Equity (ROE) of 27.32%.
What is GSK's dividend yield?
GLAXOSMITHKLINE PLC ADR offers a dividend yield of 3.41%.
What is GSK's Quality Score?
Our AI rates GSK's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy GSK?
Our AI Timing Score for GSK is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does GSK belong to?
GLAXOSMITHKLINE PLC ADR is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange
GSK AI Analysis Summary
Our AI summary for GSK: GLAXOSMITHKLINE PLC ADR (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 21.64, ROE of 27.32%, a dividend yield of 3.41%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 51.69
Price
-0.38
(-0.73%)
Day Change
|
|
|---|
GSK, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is good , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
1023
|
| Magic Formula Rank by ROE |
1023
|
| Magic Formula Rank by ROIC |
1217
|
| Price | 51.69 |
| PBV / Sector |
6.07 / 2.68
|
| Earning Per Share | 2.39 |
| PE / Sector |
21.64 / 27.65
|
| PEG or PE/Growth / Sector |
0.28 / 0.28
GREAT
|
| Average 1M Daily Value |
229.78 M
GREAT
|
| Average 1W Daily Value |
301.10 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
70% |
| Return to Investors |
|
54% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:56 |
| Symbol | GSK |
| Name | GLAXOSMITHKLINE PLC ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 2,003.45 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 104,319.44 / 256,404.20 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: 44 20 8047 5000
Website: https://www.gsk.com
Employees: 66,841
Description: GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
